MRI vs. TURBT for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study compares two ways to check if bladder cancer has grown into the muscle layer: an MRI scan (mpMRI) versus a standard surgery called TURBT (where a small tool removes a sample of the tumor). The goal is to see if the MRI can be as accurate as the surgery, so future patients might avoid an extra procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have bladder cancer that may have grown into the muscle layer, based on the look of the tumor during a cystoscopy (a camera test inside the bladder).
- You are able to do most daily activities (score 0–3 on a doctor's scale of fitness).
- You have not had a TURBT (a surgery to remove bladder tumor) in the last 4 months.
- You have not had any bladder cancer treatment in the last 6 months.
- You are not pregnant or breastfeeding.
- You are willing to have an MRI scan and a TURBT, and you have no allergies to MRI contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special MRI scan (mpMRI) to figure out how far suspected muscle-invasive bladder cancer has spread, using a new local staging approach. If the results are accurate, it may help doctors plan the most appropriate curative treatment sooner.
This study looks at how well MRI scans can detect bladder cancer after chemotherapy, before surgery to remove the bladder. It may help doctors know if the chemo is working.
This trial compares two main treatments for muscle-invasive bladder cancer: radical cystectomy (surgery to remove the bladder) and a combination of chemotherapy and radiation (chemo-radiation). The goal is to see which approach is better for patients whose cancer has not spread widely.
This study tests a combination of chemotherapy, immunotherapy, and radiation to treat muscle-invasive bladder cancer while trying to avoid bladder removal. It compares this approach to a watch-and-wait strategy, and also looks at adding maintenance immunotherapy.
This trial looks at how the immune environment around a muscle-invasive bladder tumor changes after you receive treatment before surgery (neoadjuvant therapy). The goal is to understand why some tumors respond better, which could help guide future treatments.
This study uses a special PET/CT scan to see how far your bladder cancer has spread. The results may help doctors plan the best treatment for you.
Hear when a new Urothelial Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.